Título: Inhibition of the mTOR pathway: a new mechanism of ß-cell toxicity induced by Tacrolimus. Revista: American Journal of Transplantation (2019) 19(12):3240-3249 Autores: Rodriguez-Rodriguez, A.E.; Donate-Correa, J.; Rovira, J.; Cuesto, G.; Luis-Ravelo, D.; Fernandes M..X.; Acevedo-Arozena, A.; Diekmann, F.; Acebes, A.; Torres, A.; Porrini, E.

Abstract

The mechanisms of tacrolimus‐induced β cell toxicity are unknown. Tacrolimus (TAC) and Rapamycin (Rapa) both bind to FK506‐binding protein 12 (FKBP12). Also, both molecular structures are similar. Because of this similarity, we hypothesized that TAC can also inhibit the mTOR signalling, constituting a possible mechanism of β cell toxicity. Thus, we studied the effect of TAC and Rapa over the mTOR pathway, v‐maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), and insulin secretion and content in INS‐1 β cells treated with or without glucose and palmitate and in islets from lean or obese rats. TAC and Rapa inhibited the mTOR pathway as reflected by lower levels of phospho‐mTOR, phospo-p70S6K, and phospo‐S6. The effect of Rapa was larger than TAC. Both drugs reduced the levels of MafA, insulin secretion, and content although these effects were larger with TAC. The changes on MafA and insulin metabolism were observed in cells on glucose and palmitate, in obese animals, and were absent in cells on maintenance medium or in lean animals. In silico docking and immunoprecipitation experiments confirmed that TAC can form a stable noncovalent interaction with FKBP12‐mTOR. Thus, the mTOR inhibition may be a mechanism contributing to the diabetogenic effect of TAC.